[go: up one dir, main page]

WO2008005889A3 - Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes - Google Patents

Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes Download PDF

Info

Publication number
WO2008005889A3
WO2008005889A3 PCT/US2007/072571 US2007072571W WO2008005889A3 WO 2008005889 A3 WO2008005889 A3 WO 2008005889A3 US 2007072571 W US2007072571 W US 2007072571W WO 2008005889 A3 WO2008005889 A3 WO 2008005889A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetanus toxin
toxin fragment
methods
confocal microscopy
imaging agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072571
Other languages
French (fr)
Other versions
WO2008005889A2 (en
Inventor
David Schellingerhout
Juri G Gelovani
Lucia Gertruida Leroux
David S Maxwell
Main M Alauddin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MD Anderson Cancer Center
Original Assignee
MD Anderson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MD Anderson Cancer Center filed Critical MD Anderson Cancer Center
Priority to CA002656104A priority Critical patent/CA2656104A1/en
Priority to AU2007269187A priority patent/AU2007269187A1/en
Publication of WO2008005889A2 publication Critical patent/WO2008005889A2/en
Anticipated expiration legal-status Critical
Publication of WO2008005889A3 publication Critical patent/WO2008005889A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

Methods for purifying Tetanus Toxin Fragment C comprising obtaining a supernatant comprising soluble Tetanus Toxin Fragment C and purifying Tetanus Toxin Fragment C under native conditions to obtain a substantially purified Tetanus Toxin Fragment C. Imaging agents comprising a Tetanus Toxin Fragment C and a reporter, and methods thereof. Methods comprising processing confocal microscopy datasets to provide a 360 degree average fluorescence intensity profile from the center of a spheroid towards the outer edge of the spheroid.
PCT/US2007/072571 2006-06-30 2007-06-29 Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes Ceased WO2008005889A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002656104A CA2656104A1 (en) 2006-06-30 2007-06-29 Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes
AU2007269187A AU2007269187A1 (en) 2006-06-30 2007-06-29 Tetanus Toxin Fragment C based imaging agents and methods, and confocal microscopy dataset processes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80637506P 2006-06-30 2006-06-30
US60/806,375 2006-06-30

Publications (2)

Publication Number Publication Date
WO2008005889A2 WO2008005889A2 (en) 2008-01-10
WO2008005889A3 true WO2008005889A3 (en) 2008-12-31

Family

ID=38895389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072571 Ceased WO2008005889A2 (en) 2006-06-30 2007-06-29 Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes

Country Status (4)

Country Link
US (1) US20080044348A1 (en)
AU (1) AU2007269187A1 (en)
CA (1) CA2656104A1 (en)
WO (1) WO2008005889A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228925A1 (en) * 2015-08-28 2018-08-16 University Of Massachusetts Quantifying Net Axonal Transport in Motor Neuron Pathologies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009057A2 (en) * 1997-08-14 1999-02-25 Institut Pasteur Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns
US6445543B1 (en) * 1998-06-04 2002-09-03 Seagate Technology Llc Slider with pressure relief trenches
WO2005094497A2 (en) * 2004-03-24 2005-10-13 Emory University Systemic delivery of therapeutics to central nervous system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009057A2 (en) * 1997-08-14 1999-02-25 Institut Pasteur Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns
US6445543B1 (en) * 1998-06-04 2002-09-03 Seagate Technology Llc Slider with pressure relief trenches
WO2005094497A2 (en) * 2004-03-24 2005-10-13 Emory University Systemic delivery of therapeutics to central nervous system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROUX ET AL.: "Internalization of a GFP-tetanus toxin C-terminal fragment fusion protein at mature mouse neuromuscular junctions", no. 30, 14 July 2005 (2005-07-14), pages 79 - 89, XP005022100 *

Also Published As

Publication number Publication date
WO2008005889A2 (en) 2008-01-10
CA2656104A1 (en) 2008-01-10
US20080044348A1 (en) 2008-02-21
AU2007269187A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
BRPI0819869A2 (en) process for the production of a brewer's wort, use of a process, wort, and enzyme mixture.
ATE427965T1 (en) ANTIBODIES AGAINST 25-HYDROXYVITAMIN D
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
BRPI0715243A2 (en) "method of increasing ethanol production and z. mobilis strain"
WO2009035494A3 (en) Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
EP1990374A4 (en) C. I. 57: 1 RED PIGMENT AND PROCESS FOR PRODUCING THE SAME
WO2006092213A8 (en) Pyrazolylcarboxanilides
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2009158658A3 (en) Induction of flocculation in photosynthetic organisms
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2020068920A3 (en) Lung protease nanosensors and uses thereof
NZ595792A (en) Antibodies specific to cadherin-17
MY142988A (en) Novel aminobenzophenone compounds
WO2008017074A3 (en) Dyes and precursors and conjugates thereof
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2007059430A3 (en) Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
WO2009030224A3 (en) Novel quinazoline compounds and the use thereof for treating cancerous diseases
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
NO20053206D0 (en) Process for producing ketocarotenoids in the cultivation of genetically modified organisms.
FR2885134B1 (en) PROCESS FOR PREFINING RAW OIL WITH MODERATE HYDROCONVERSION IN SEVERAL STEPS OF VIRGIN ASPHALT IN THE PRESENCE OF DILUENT
IL193560A0 (en) Novel microorganism and method for producing dodecahydro-3a,6,6,9a-
MY147463A (en) The dehydrogenation of mixed alcohols
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
WO2009049966A3 (en) Methods and tools for prognosis of cancer in her2+ patients
WO2008005889A3 (en) Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812508

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007269187

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2656104

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007812508

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007269187

Country of ref document: AU

Date of ref document: 20070629

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU